{
    "nct_id": "NCT01029132",
    "title": "Characteristics of Treatment Responders to Galantamine Administration in the Patients With Alzheimer's Disease",
    "status": "COMPLETED",
    "last_update_time": "2016-01-04",
    "description_brief": "To investigate the characteristics of treatment responders to galantamine.",
    "description_detailed": "The purposes of this study are:\n\n1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks.\n2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.",
    "phase": [
        "NA"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "galantamine"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial description tests galantamine (an Alzheimer\u2019s treatment) to identify characteristics of treatment responders. Galantamine is a small-molecule cholinesterase inhibitor that also allosterically potentiates nicotinic acetylcholine receptors; it is used to produce symptomatic cognitive improvement in mild-to-moderate Alzheimer\u2019s disease rather than to modify underlying pathology. \ue200cite\ue202turn0search0\ue202turn0search7\ue201",
        "Act: Extracted details from the literature and product information \u2014 drug name: galantamine (brand Razadyne); drug type: small molecule (oral tablets/ER capsules); mechanism: reversible acetylcholinesterase inhibition + nicotinic receptor allosteric modulation; clinical intent: symptomatic cognitive enhancement (improves cognition, function over months) and indicated for mild\u2013moderate Alzheimer\u2019s dementia per product labeling. The provided trial aim (\u201ccharacteristics of treatment responders to galantamine\u201d) therefore aligns with assessing response to a cognitive enhancer rather than a disease-modifying biologic. \ue200cite\ue202turn0search3\ue202turn1search0\ue202turn1search2\ue201",
        "Reflect: Classification check \u2014 under the definitions, galantamine is not a biologic and does not target core AD pathology (amyloid/tau) for disease modification, so it does not fit 'disease-targeted biologic' or 'disease-targeted small molecule' (the latter reserved for small molecules aimed at pathology). It is a symptomatic cholinergic cognitive enhancer, so the correct category is 'cognitive enhancer'. The trial text gives no indication of neuropsychiatric-targeted outcomes or use of diagnostics only; no placebo information is provided in the short description. \ue200cite\ue202turn0search6\ue201",
        "Web search results (sources used): 1) PubMed review noting galantamine is a reversible acetylcholinesterase inhibitor and enhances acetylcholine action at nicotinic receptors; describes symptomatic cognitive benefits. \ue200cite\ue202turn0search0\ue201. 2) PubMed/PNA S and related preclinical work describing nicotinic potentiation and AChE inhibition mechanisms. \ue200cite\ue202turn0search3\ue201. 3) DrugBank summary describing galantamine\u2019s dual mechanism and that it is not considered disease-modifying (approved as symptomatic treatment). \ue200cite\ue202turn0search7\ue201. 4) Drugs.com / prescribing information (Razadyne label) with indication for mild-to-moderate Alzheimer\u2019s dementia and dosing/adverse-effect information. \ue200cite\ue202turn1search0\ue201. 5) FDA information page on galantamine (Razadyne) with regulatory/safety context. \ue200cite\ue202turn1search2\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests galantamine, a small-molecule reversible acetylcholinesterase inhibitor that also allosterically potentiates nicotinic acetylcholine receptors. Its mechanism modifies cholinergic neurotransmission and receptor function to produce symptomatic cognitive improvement rather than targeting core AD pathology (amyloid/tau). This aligns with CADRO's focus on neurotransmitter systems.",
        "Act: Extracted details from the description \u2014 drug: galantamine (Razadyne); drug type: small molecule; mechanism: reversible acetylcholinesterase inhibition + nicotinic receptor allosteric potentiation; clinical intent: symptomatic cognitive enhancement (identify characteristics of treatment responders). Based on these specifics, assign 'D) Neurotransmitter Receptors'.",
        "Reflect: Confirmed that galantamine does not target amyloid, tau, ApoE/lipids, inflammation, proteostasis, vasculature, or other core disease-modifying pathways, and is not a diagnostic-only intervention. Therefore 'D) Neurotransmitter Receptors' is the most specific CADRO match. If the trial had aimed at disease modification or multiple distinct biological pathways, 'R) Multi-target' or another category would be considered, but that is not indicated here.",
        "Web search results (sources used / explanatory notes): 1) PubMed review noting galantamine is a reversible acetylcholinesterase inhibitor and enhances acetylcholine action at nicotinic receptors (describes symptomatic cognitive benefits). 2) PubMed/preclinical literature describing dual mechanism (AChE inhibition + nicotinic potentiation). 3) DrugBank summary describing galantamine\u2019s dual mechanism and that it is approved as a symptomatic treatment (not disease-modifying). 4) Drugs.com / prescribing information (Razadyne label) with indication for mild-to-moderate Alzheimer\u2019s dementia and dosing/adverse-effect information. 5) FDA information page on galantamine (Razadyne) with regulatory/safety context. These sources support the mechanism and symptomatic intent used above."
    ]
}